Dear Reader,

I hope this email finds you well. I'm thrilled to share an exciting update regarding Citius Pharmaceuticals (NASDAQ: CTXR) that's sure to pique your interest.

CTXR experienced an early run of over 25% from yesterday's close, demonstrating significant momentum in the market. While the market has retraced to 77, this dip has created a new opp for researchers to consider.

Despite the fluctuations, the underlying potential of Citius Pharmaceuticals remains strong. As the company continues to make strides in its innovative pipeline and clinical developments, there's ample reason to remain optimistic about its future prospects.

I encourage you to continue your research into Citius Pharmaceuticals (NASDAQ: CTXR) and stay informed about the latest developments. With each milestone and breakthrough, CTXR solidifies its position as a key player in the pharmaceutical industry.

Whether you're a seasoned researcher or someone exploring new opp’s, CTXR offers an exciting journey of discovery and potential growth. Don't miss out on this chance to be part of something extraordinary.

Add Citius Pharmaceuticals (NASDAQ: CTXR) to your watchlist now!

Warm regards,

Max Masters

Co-founder, Market Tips Newsletter

Data is provided from third-party sources and Market Tips is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc.laim.er here. 

Pursuant to an agreement, Momentum Media LLC has been hired for a period beginning on 04/17/2024 and ending on 04/18/2024 to publicly disseminate information about (CTXR:US) via digital communications. We have been paid forty two thousand five hundred dollars USD. We own zero shares of (CTXR:US)